F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

A recent vote by an F.D.A. panel to endorse the broader use of peptides in compounding pharmacies has sparked concern over potential overprescribing and regulation issues. Compounding pharmacies, which are lightly regulated, have seen a surge in their business, making this decision significant. Critics worry that this move could lead to an unregulated prescribing boom, raising questions about patient safety and oversight. It’s a pivotal moment that highlights the tension between fostering innovation and ensuring stringent medical standards.